Clinical Trial Update: Effect of Ferric Carboxymaltose on Exercise Capacity in Patients With Iron Deficiency and Chronic Heart Failure [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating ferric carboxymaltose to improve exercise capacity in patients with iron deficiency and chronic heart failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Iron Deficiency

Drugs mentioned

• Ferric carboxymaltose (ferric carboxymaltose)

Snippet

Sponsor: Vifor Pharma | Conditions: Iron Deficiency, Chronic Heart Failure | Phase 3 | Status: COMPLETED